Chemistry:Mosapride

Short description: Chemical compound

Mosapride

Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	A03FA09 (WHO)
Identifiers
IUPAC name 4-Amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]morpholin-2-yl]methyl]benzamide
CAS Number	112885-41-3 N
PubChem CID	119584
IUPHAR/BPS	242
DrugBank	DB11675 Y
ChemSpider	106780 Y
UNII	I8MFJ1C0BY
KEGG	D08236 Y
ChEBI	CHEBI:94373
ChEMBL	ChEMBL60889 Y
Chemical and physical data
Formula	C21H25ClFN3O3
Molar mass	421.90 g·mol−1
3D model (JSmol)	Interactive image
SMILES Clc1cc(c(OCC)cc1N)C(=O)NCC3OCCN(Cc2ccc(F)cc2)C3
InChI InChI=1S/C21H25ClFN3O3/c1-2-28-20-10-19(24)18(22)9-17(20)21(27)25-11-16-13-26(7-8-29-16)12-14-3-5-15(23)6-4-14/h3-6,9-10,16H,2,7-8,11-13,24H2,1H3,(H,25,27) Y Key:YPELFRMCRYSPKZ-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Mosapride is a gastroprokinetic agent that acts as a selective 5HT₄ agonist. The major active metabolite of mosapride, known as M1, additionally acts as a 5HT₃ antagonist, which accelerates gastric emptying throughout the whole of the gastrointestinal tract in humans, and is used for the treatment of gastritis, gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome. It is recommended to be taken on an empty stomach (i.e. at least one hour before food or two hours after food).

In addition to its prokinetic properties, mosapride also exerts anti-inflammatory effects on the gastrointestinal tract which may contribute to some of its therapeutic effects. Mosapride also promotes neurogenesis in the gastrointestinal tract which may prove useful in certain bowel disorders. The neurogenesis is due to mosapride's effect on the 5-HT₄ receptor where it acts as an agonist.

Its common side effects include dry mouth, abdominal pain, dizziness, headache, insomnia, malaise, nausea, diarrhea and sometimes constipation. Unlike some other prokinetic agents, mosapride has little effect on potassium channels, no effect on hERG transfected cells, and no effect on cardiovascular function that could be detected in tests on humans. Due to the pharmacokinetics of mosapride, it would take 1,000–3,000 times the therapeutic dose to elicit cardiovascular effects.